PMID- 35979215
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230328
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 9
DP  - 2022
TI  - Efficacy and safety of netarsudil/latanoprost fixed-dose combination vs. 
      monotherapy in open-angle glaucoma or ocular hypertension: A systematic review 
      and meta-analysis of randomized controlled trials.
PG  - 923308
LID - 10.3389/fmed.2022.923308 [doi]
LID - 923308
AB  - OBJECTIVE: As monotherapy is insufficient for some patients, the existing 
      fixed-dose combination (FDC) requires two or more daily administrations with 
      declining adherence. The present study compared the efficacy and safety of 
      netarsudil/latanoprost FDC with monotherapy of its individual components in 
      patients with glaucoma. METHODS: A systematic literature search was performed for 
      studies comparing netarsudil/latanoprost fixed-dose combination (FDC) vs. 
      monotherapy in patients with glaucoma. The primary endpoints included intraocular 
      pressure (IOP), intraocular pressure reduction percentage (IOPR%) and adverse 
      events (AEs). RESULTS: Three randomized controlled trial studies (RCTs) involving 
      1,692 patients (FDC: 556, netarsudil: 577, latanoprost: 559) were included in 
      this meta-analysis. FDC was more effective than netarsudil, with significantly 
      lower diurnal IOP over three time points (8:00 a.m., 10:00 a.m., 4:00 p.m.), mean 
      diurnal IOP (MD = -2.36 [-3.08, -1.63], P < 0.00001) and higher IOPR% (MD = 9.60 
      [7.86, 11.33], P < 0.00001). When comparing FDC with latanoprost, both mean 
      diurnal IOP (MD = -1.64 [-2.05, -1.23], P < 0.00001) and diurnal IOP across 3 
      time points were significantly lower with FDC than with latanoprost, while FDC 
      induced significantly higher IOPR% (MD = 6.09 [4.40, 7.77], P < 0.00001). 
      Incidence of total AEs was similar between netarsudil and FDC, but higher with 
      FDC than with latanoprost. CONCLUSION: Netarsudil/latanoprost FDC appears to be 
      superior to netarsudil or latanoprost alone, with better ocular hypotensive 
      effects. However, there are concerns that netarsudil/latanoprost FDC was 
      associated with a significantly higher incidence of AEs specifically compared 
      with latanoprost. SYSTEMATIC REVIEW REGISTRATION: 
      https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=311956.
CI  - Copyright (c) 2022 Luo, Jiang, Hao, Fang, Wei and Zhang.
FAU - Luo, Nachuan
AU  - Luo N
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Jiang, Xun
AU  - Jiang X
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Hao, Meiqi
AU  - Hao M
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Fang, Zige
AU  - Fang Z
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
AD  - Jiangxi Medical College, Nanchang University, Nanchang, China.
FAU - Wei, Yiping
AU  - Wei Y
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
FAU - Zhang, Wenxiong
AU  - Zhang W
AD  - Department of Thoracic Surgery, The Second Affiliated Hospital of Nanchang 
      University, Nanchang, China.
LA  - eng
PT  - Systematic Review
DEP - 20220801
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC9376331
OTO - NOTNLM
OT  - fixed-dose combination
OT  - glaucoma
OT  - latanoprost
OT  - meta-analysis
OT  - netarsudil
OT  - topical medication
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/08/19 06:00
MHDA- 2022/08/19 06:01
PMCR- 2022/08/01
CRDT- 2022/08/18 02:14
PHST- 2022/04/19 00:00 [received]
PHST- 2022/07/12 00:00 [accepted]
PHST- 2022/08/18 02:14 [entrez]
PHST- 2022/08/19 06:00 [pubmed]
PHST- 2022/08/19 06:01 [medline]
PHST- 2022/08/01 00:00 [pmc-release]
AID - 10.3389/fmed.2022.923308 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2022 Aug 1;9:923308. doi: 10.3389/fmed.2022.923308. 
      eCollection 2022.